KLK3 and prostate cancer: Published studies have suggested that lncRNAs have potential as biomarkers in human fluids; for example, compared with PSA (prostate-specific antigen) serum levels, the lncRNA PCA3 found in patient urine samples allowed for a more sensitive and specific diagnosis of prostate cancer [14–17].